Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intraabdominal malignancies

A total of 25 patients with severe peritoneal dissemination underwent chemo hyperthermic peritoneal perfusion (CHPP). The primary tumors in these patie nts comprised colorectal cancer (n = 14), ovarian cancer (n = 6), cervical cancer, (n = 1), small bowel cancer (n = 1), pseudomyxoma retroperitonei (n = 1), cystoadenocarcinoma of liver (n = 1), and pancreas cancer (n = 1). T he intraperitoneal perfusion was carried out with a magnet pump for 60 min. The heated perfusate contained anticancer drugs to act synergistically wit h the hyperthermia. The intraperitoneal temperature was maintained at 42.0- 42.5 degrees C. Eight of 25 patients showed CR, four PR, ten NC, and three PD, and the percentage (CR+PR) representing the overall efficacy rate was 4 8.0%. The morbidity rate was 8% (2/25) and there was no treatment-associate d mortality. The percentage (CR+PR) of the patients with colorectal cancer was 57%; ovarian cancer, 50%; and other malignancies, 20%. The 1 year- and 3 year-survival rates of all the patients were 55% and 26%, respectively. T he median survival periods of the CR, PR, NC, and PD groups were 4.0, 1.0, 1.0, and 0.7 years, respectively. The survival curve of the CR group was th e best of all the groups (P = 0.02). These results indicated that CHPP was a feasible therapy and exerted a direct anticancer effect on peritoneal dis semination especially in the case of ovarian cancer, and the prognosis of c omplete responders was improved.